Literature DB >> 22553639

Radiofrequency ablation technique eradicating palpebral margin neoplasm.

Tian-Yu Jiang1, Xing-Lin Wang, Wei Suo, Qing-Hua He, Hong-Yu Xiao.   

Abstract

AIM: To report the study on radiofrequency ablation technique for eradication of palpebral margin neoplasm and its clinical effects.
METHODS: One hundred and six cases with the palpebral margin neoplasm were performed surgical removal with radiofrequency ablation technique. The 1-2 months postoperative follow-up was investigated and the lost cases were excluded from statistics. The continuing follow-up lasted about 6-16months.
RESULTS: One hundred cases underwent one treatment and 6 cases underwent two treatments. Six cases were missed. All the cases followed up healed well without pigmentation or scar left, nor eyelash loss or palpebral margin deformation. No case was recurrent.
CONCLUSION: Radiofrequency ablation has significant efficiency in eradicating the palpebral margin neoplasm.

Entities:  

Keywords:  palpebral margin neoplasm; radiofrequency ablation

Year:  2011        PMID: 22553639      PMCID: PMC3340698          DOI: 10.3980/j.issn.2222-3959.2011.02.16

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  13 in total

1.  [Treatment of benign prostatic hyperplasia by radiofrequency (TUNA): a monocentric study of 28 cases treated in ambulatory surgery].

Authors:  S Le Gal; Y Fouques; S Mallick; L Taksin; S Le Toquin-Bernard; O Frachet; H Bensadoun
Journal:  Prog Urol       Date:  2008-12-18       Impact factor: 0.915

2.  Pupil damage after periorbital laser treatment of a port-wine stain.

Authors:  Stefan Hammes; Albert Augustin; Christian Raulin; Hans-Michael Ockenfels; Edda Fischer
Journal:  Arch Dermatol       Date:  2007-03

3.  Enhanced full-face skin rejuvenation using synchronous intense pulsed optical and conducted bipolar radiofrequency energy (ELOS): introducing selective radiophotothermolysis.

Authors:  Neil S Sadick; Macrene Alexiades-Armenakas; Patrick Bitter; George Hruza; R Stephen Mulholland
Journal:  J Drugs Dermatol       Date:  2005 Mar-Apr       Impact factor: 2.114

Review 4.  Hepatic ablation for neuroendocrine tumor metastases.

Authors:  Shishir K Maithel; Yuman Fong
Journal:  J Surg Oncol       Date:  2009-12-15       Impact factor: 3.454

Review 5.  Renal ablative therapy: radiofrequency ablation and cryoablation.

Authors:  Jay D Raman; David W Hall; Jeffrey A Cadeddu
Journal:  J Surg Oncol       Date:  2009-12-15       Impact factor: 3.454

Review 6.  Endoscopic therapy using radiofrequency ablation for esophageal dysplasia and carcinoma in Barrett's esophagus.

Authors:  Frederike G I van Vilsteren; Jacques J G H M Bergman
Journal:  Gastrointest Endosc Clin N Am       Date:  2010-01

Review 7.  The use of radiofrequency ablation in the treatment of musculoskeletal tumors.

Authors:  Dustin Volkmer; Michael Sichlau; Timothy B Rapp
Journal:  J Am Acad Orthop Surg       Date:  2009-12       Impact factor: 3.020

Review 8.  Meta-analysis of ablation of atrial flutter and supraventricular tachycardia.

Authors:  Peter Spector; Matthew R Reynolds; Hugh Calkins; Manu Sondhi; Yingxin Xu; Amber Martin; Catherine J Williams; Isabella Sledge
Journal:  Am J Cardiol       Date:  2009-09-01       Impact factor: 2.778

9.  Blepharoplasty in the post-laser in situ keratomileusis patient: preoperative considerations to avoid dry eye syndrome.

Authors:  Bobby S Korn; Don O Kikkawa; David J Schanzlin
Journal:  Plast Reconstr Surg       Date:  2007-06       Impact factor: 4.730

10.  Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates.

Authors:  Gladwin C Hui; Kemal Tuncali; Servet Tatli; Paul R Morrison; Stuart G Silverman
Journal:  J Vasc Interv Radiol       Date:  2008-07-21       Impact factor: 3.464

View more
  1 in total

1.  A technique for periorbital syringomas: intralesional radiofrequency ablation.

Authors:  Li-Ping Huang; Leng Zhang; Xing-Lin Wang; Xiao-Cui Liu; Tian-Yu Jiang; Bi-Weng Lin
Journal:  Int J Ophthalmol       Date:  2012-04-18       Impact factor: 1.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.